65,437 trials
Cystic Fibrosis
Primary: Treatment Period 1 (Treatment Cohorts): Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse…
Chagas Disease
Primary: Part 1 - Percentage of Sero-reduction or Sero-conversion (Cured Subjects) — 32.9; 18.9 Percentage of subjects
Intermittent Explosive Disorder
Primary: Safety and Tolerability — 28; 21; 0; 0 participants
Metastatic Castration-Resistant Prostate Cancer
Primary: Median Time on Treatment — 11 weeks
Heart Failure, Systolic · Diabetes Mellitus, Type 2
Primary: Change From Baseline Aerobic Exercise Capacity at 12 Weeks — 0.67; -0.53 mL/kg/min — p=0.083
Insulin Sensitivity · Multiple Mitochondrial Dysfunctions Syndrome
Primary: Change in Insulin Sensitivity — 3.18; 3.85; 3.57; 5.22 mg/kg.min per µU/ml
Metabolic Syndrome
Primary: Body Weight — 75.2; 74.97; 74.41; 74.39 kg
Follicular Lymphoma
Primary: Number of Participants With Overall Response Rate (ORR) — 0; 0; 0; 0 participants
Anemia · Cancer Fatigue · Chronic Lymphocytic Leukemia
Primary: Treatment Success and Feasibility of Autologous Activated T-cells Infusion, Determined by Number of Participants That Achieved Target-Activated T-cell Dose Without DLT…
Fever · Malaria
Primary: Number of Subjects With a Fever Who Receive a Malaria Test From Any Source — 384; 402; 443; 391 Participants
Cardiac Disease · Dementia · Inflammatory Disease
Primary: Overall Image Quality Scores
Parenteral Nutrition Associated Liver Disease PNALD · Cholestasis
Primary: Number of Patients With Progression to Small Bowel Transplantation. — 19 Participants
Advanced Renal Cell Carcinoma
Primary: Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or Sorafenib — 11.9; 9.1 Months
Dysmenorrhea
Primary: Sum of Total Pain Relief (TOTPAR) Over 0-12 Hours — 29.18; 24.87 Scores on a scale * hours — p=< 0.001
Atrophic Acne Scars
Primary: Acne Scar Assessment Scale (ASAS) — 2.65; 3.71 units on a scale